



Company Overview



About TK Holdings

Stock code	:	2283.HK
Listing date	:	December 2013
No. of issued share capital (as at 26 March 2021)	:	833,260,000 shares
Share price (as at 26 March 2021)	:	HK\$2.78
Market cap (as at 26 March 2021)	:	HK\$2.32 billion

Stock Price Performance




Results Highlights


- In 1H2020, most of the major customers postponed orders due to the impact of the COVID-19 epidemic, dragged down the Group's interim results. In 2H2020, with Chinese government's effective anti-epidemic measures, economic activities recovered and the market gradually coped with the new normal amid the epidemic, and led to the resumption of new product development and launch
- Downstream segments Medical and health care, Automobiles, Mobile phones and wearable devices recorded growth
- Considerable orders secured on hand reached HK\$925.2million, increased by
 4.8% yoy
- A high technology company with high dividend payout, payout ratio at 39.7%

2020 Annual Results

HK\$'000	2020	yoy growth
Revenue	2,033,419	↓12.0%
Net Profit	209,687	↓30.5%
Basic earnings per share (HK cents)	25.0	↓30.6%
Proposed final dividend per share (HK cents)	8.0	↓11.1%
Full-year dividend payout ration (Including interim dividend: 2 HK cents)	39.7%	↑1.0p.p.
Gross profit margin	26.2 %	↓2.7p.p.
Net profit margin	10.3%	↓2.8p.p.



Business Review





Achieved V-Shaped Rebound Despite Covid-19 Impact




1H2020

- Production resumption was delayed by a week to 10 February 2020
- Insufficient work resumption rate due to the travel restrictions

- Postponement of delivery for most overseas orders at the request of customers
- Low capacity utilization as a result
- Salaries of all EDs and senior management reduced by 20% since 1 April 2020
- Various cost-saving measures were effectively implemented

Maintained Strong Cash Flow and Cash Position



- 2H2020
- Other countries gradually cope with the changes from the epidemic and the new normal lifestyle, demand for certain consumer electronic products recovered steadily with V-shaped rebound
- Packed orders in 2H2020 and sales were better than expected, rebounded to a similar level yoy of last year
- Apart from the improving market conditions, sales recovery in 2H2020 were mainly contributed from:
 - Continuous Diversification of products and customers
 - Molding technology advantage and the guarantee of product quality
 - ✓ Gradual commencement of projects from new customers



Diversified Customer Network























2020 top six customers

#	Company name	Industry	Product category
1	A leading smart phone accessory brand	Mobile phones and wearable devices	Mold and Plastic products
2	A leading health care product brand	Medical and health care	Mold and Plastic products
3	A leading smart phone brand	Mobile phones and wearable devices	Mold and Plastic products
4	A leading wireless headsets brand	Mobile phones and wearable devices	Mold and Plastic products
5	Polycom	Commercial telecommunications equipment	Mold and Plastic products
6	A leading smart home product brand	Smart home	Mold and Plastic products

The top six customers contributed 52.0% of TK's revenue in 2020



Projects on hand for 2021



Industry	Amount (HK\$'000)
Automobile	418.8
Medical and health care	167.1
Mobile phones and wearable devices	94.6
Smart home	78.3
Others	63.3
Household electric appliance	60.9
Commercial telecommunications equipment	33.3
Digital devices	8.9
Total	925.2

Projects on hand as at 31 December 2020


Amounted to HK\$ 925.2 million


▲ 4.8% compared with 2019-year end




Development Strategies







2020 Annual Results





Key Financials



For the year ended 31 December				■ In 1 ma ord
HK\$ '000	2019	2020	Change	CO the
Revenue	2,310,842	2,033,419	↓12.0%	the pro
Gross profit	667,475	532,633	↓20.2%	yea
Operating profit	361,523	234,858	↓35.0%	- Daile
Profit attributable to owners of the Company	301,803	209,687	↓30.5%	■ Daily the i qua
Basic earnings per share (HK cents)	36	25	↓30.6%	by m the e
Gross profit margin	28.9%	26.2%	↓2.7p.p.	Grou and high
Net profit margin	13.1%	10.3%	↓2.8p.p.	mac
Dividend per share (HK cents) - Interim - Final	5.0 9.0	2.0 8.0	↓60.0% ↓11.1%	■ Hea divid
Dividend payout ratio	38.7%	39.7%	↑1.0p.p.	■ Posi com

• In 1H2020, most of the Group's major customers postponed orders due to the impact of the COVID-19 epidemic. In 2H2020, the market gradually coped with the new normal and led to new product development resumption and market plans launch. Full year decline narrowed

- Daily operation was impacted by the implementation of the quarantine and social restrictions by many countries in respond to the epidemic
- In1H2020, the customers of the Group postponed delivery dates and new orders, resulting in a higher idleness ratio of the machines

- Healthy financials support high dividend payout ratio
- Positioned as a high technology company with high dividend payout



Segment Review – Mold Fabrication





Revenue

700.2
HK\$ million
18.5%

27.4%
Gross Profit Margin

17.8p.p.

- Since the Sino-US trade war in 2018, the Group was under price pressure from its customers. Together with the keen competition from the overseas peers, the gross profit margin was squeezed
- The Group made great efforts to explore new customers in medical and healthcare segment over the past few years. The increase in mold delivery during the year drove a segment growth of 165.5%





Segment Review – Plastic Products





Revenue

25.6%
Gross Profit Margin
11.1p.p.

Segment revenue decreased mainly due to :

- Benefiting from the Group's diversified customer portfolio strategy and the Chinese government's effective anti-epidemic measures, the Group's production was quickly recovered and its revenue decline for the year was significantly narrowed compared to 1H2020
- Mobile phones and wearable devices segment revenue increased 3.7% yoy, mainly due to (1) new products launched by a smartphone cases brand customer, (2) products of a wireless headset brand customer were well received by the public, (3) however, a smartphone brand customer reduced their orders for standard products
- Medical and health care segment revenue increased 7.0% yoy. The Group already obtained several new large customers, including an overseas brand customer engaging in the medical consumables business and a domestic listed company. Several sets of molds were successfully tailor-made and expected to be used in the mass production of plastic components in 2021







Revenue Analysis



Breakdown by business segment



Breakdown by downstream industry





High-growth segments	yoy growth
Medical and health care	↑41.0%
Automobiles	↑6.2%
Mobile phones and wearable devices	↑3.7%




Gross Profit Analysis














 Affected by Covid-19 in 1H2020, idleness ratio of machines increased resulting from the delayed production of projects




Net Profit Analysis



Net profit & net profit margin

HK\$ million



Key expenses

HK\$ million	2019	2020	Change
Selling expenses	80.7 (3.5% of revenue)	71.1 (3.5% of revenue)	↓11.8%
Administrative expenses	269.6 (11.7% of revenue)	254.7 (12.5% of revenue)	↓5.5%
Finance Income / (expenses) - net*	-1.4	5.0	- to +
Income tax expense	58.7 (16.3% of profit before tax)	30.9 (12.8% of profit before tax)	↓47.4%

^{*}Finance Income/ (expenses) -net = Interest income – Interest expenses



Key Financial Indicators



HK\$ '000	As at 31 December 2019	As at 31 December 2020	Change
Net current assets	619,628	835,259	↑34.8%
Cash and cash equivalents	735,110	1,069,120	↑45.4%
Current ratio	170.1%	182.5%	↑12.4p.p.
Quick ratio	125.2%	138.3%	↑13.1p.p.
Gearing ratio	20.3%	20.2%	↓0.1p.p.
Net gearing ratio#	0.0%	0.0%	
Return on assets	13.0%	8.2%	↓4.8p.p.
Return on equity	25.3%	15.0%	↓10.3p.p.


[#] Net gearing ratio = (Total borrowings – cash & deposits for bank borrowings) / Total equity x 100% (Net cash as at 31 Dec 2019 and 31 Dec 2020 were HK\$ 493,150,000 and HK\$ 786,885,000 respectively, thus Net gearing ratio is 0%.)

For the year ended 31 December	2019	2020	Change
Net cash generated from operating activities (HK\$'000)	443,800	518,110	↑16.7%
Inventory turnover days	83	105	↑22
Trade receivable turnover days	49	54	↑ 5
Trade payable turnover days	65	74	↑9



Production Base and Capacity








Shareholding Structure








Number of issued shares (as of 26 March 2021): 833,260,000 shares

^{*}Issued share capital of Eastern Mix Company Limited is held by Mr. Alan Li, Mr. Michael Yung and Mr. Lee Leung Yiu at the stake of 45.0%, 28.0% and 27.0% respectively



Corporate Milestones






- Expanded business to plastic injection molding
- Began operations in TK Technology Park
- Awarded "Excellence in Operations Award" by Hong Kong Mold and Die Council of Federation of Hong Kong Industry
- TK Group's subsidiary,
 TK International was
 awarded "Best Quality
 Award" by Whirlpool and
 "SanDisk Supplier Best in
 Class Performance Award,
 2011" by SanDisk
- Acquired S&B Company in Germany
- Acquired Nypro Tool Shenzhen Assets
- Recognised as the largest PRC manufacturer of plastic injection molds with level above MT3 in 2015 (in terms of export value) by Ipsos
- Received the "2016 Hong Kong Awards for Industries: Upgrading and Transformation Award" from the Hong Kong Young Industrialists Council
- Newly added 3 intelligently flexible production lines
- Become a constituent of the MSCI Hong Kong Small Cap Index
- Awarded the "Excellence Award 2018 for Listing Companies – Main Board" by the Hong Kong Economic Journal
- Received the "2018 Hong Kong Awards for Industries: Upgrading and Transformation Award" from the Hong Kong Young Industrialists Council again
- Acquired all of its assets of Techco Silicone & Technology Co., Ltd. to expand the technology and production capacity of the Group in silicone mold and product solutions




Management Team



Name & title		Major responsibilities	Years of professional experience
	Mr. Alan Li Chairman & Executive Director	 One of the founders of the Company Responsible for overall management and strategic planning 	 More than 30 years of professional experience in plastic mold fabrication and plastic injection molding Rich experience in business management in the manufacturing industry
	Mr. Michael Yung CEO & Executive Director	 Responsible for business development and daily operations 	 About 30 years of experience in plastic mold fabrication and plastic injection molding
	Mr. Lee Leung Yiu Executive Director	 One of the founders of the Company Responsible for procurement 	 About 30 years of experience in plastic mold fabrication and plastic injection molding
	Mr. Franky Cheung CFO & Executive Director	 Responsible for finance, taxation, audit and investment 	 About 30 years of experience in the field of auditing, accounting and corporate finance Formerly worked at Deloitte Ross Tohmatsu, FORTUNE 500 manufacturing company, and manufacturing companies listed in Hong Kong and the U.S.



Appendix





Business Overview






Provide customised, cost-effective and high-precision products and services to renowned multi-national companies



高增長業務板塊



Smart home




Medical and health care



Mobile phones and wearable devices



Mobile phones and wearable devices





Vertically Integrated Business Model



TK Group (2283.HK)

Design of machinery and molds

- Major raw materials:
 - Steel
 - Plastic resin
- 2 research cooperation agreements with the National Laboratory for Material Formation and Molds of Huazhong University of Science and Technology in Shenzhen

Mold fabrication 2020 GP margin: 27.4%

- 71 patents:
 - 5 invention patents
 - 6 software patents
 - 60 utility model patents
- Technological capabilities to comply with the stringent requirements of downstream customers:
 - Tooling-life Precision
 - Reliability Quality
- Meet the MT1 precision level as defined by the "National Standard of the People's Republic of China GB/T14486-2008—Dimensional Tolerances for Moulded Plastic Parts'
- Value-added services that minimises costs, e.g. product optimisation, shortening of product development cycle and efficiency improvement

Plastic products 2020 GP margin: 25.6%

- 116 utility model patents
 - 1 invention patent
 - 115 utility model patents
- Technological capability to serve industry leaders
- Performance molding
- Standard molding
- Special decorative molding
- Acquired the international certification of ISO13485 (Medical Device — Quality Management Systems — Requirements for Regulatory Purposes)

Extensive end applications

- → Mobile phones and wearable devices
- → Medical and health care
- → Commercial telecommunication equipment
- → Automobile























Consolidated Income Statement



	For the year ended 31 December	
HK\$ '000	2019	2020
Revenue	2,310,842	2,033,419
Cost of sales	(1,643,367)	(1,500,786)
Gross profit	667,475	532,633
Other income	50,147	58,835
Other losses — net	(5,842)	(30,761)
Selling expenses	(80,690)	(71,130)
Administrative expenses	(269,567)	(254,719)
Operating profit	361,523	234,858
Interest income	20,220	15,025
Interest expenses	(21,615)	(9,991)
Share of net profit of an associate accounted for using the equity method	371	650
Profit before income tax	360,499	240,542
Income tax expense	(58,696)	(30,855)
Profit for the Year attributable to owners of the Company	301,803	209,687
Basic earnings per share (HK cents)	36	25
Dividends per share (HK cents)	14	10
Gross profit margin	28.9%	26.2%
Net profit margin	13.1%	10.3%



Consolidated Statement of Financial Position



K\$ '000	As at 31 December 2019	As at 31 December 2020
Non-current assets	820,598	724,362
Investment in an associate	15,526	16,170
Property, plant and equipment	592,278	556,903
Intangible assets	13,831	24,14
Prepayments for property, plant and equipment	22,812	10,083
Right-of-use assets	142,530	83,43
Financial assets at fair value through profit or loss	33,62 <mark>1</mark>	33,62
	4.500.015	
Current assets	1,503,945	1,847,94
Inventories	397,04 <mark>1</mark>	447,09
Amount due from a related company	074.704	10,89
Trade and other receivables	371,794	320,83
Deposits for bank borrowings	134,594	148,23
Restricted cashes	17,638	44
Cash and cash equivalents	582,878	920,44
Total assets	2,324,543	2,572,31
Non-current liabilities	248,761	165,06
Bank borrowings	75,91 <mark>1</mark>	58,43
Lease liabilities	92,671	19,53
Deferred income on government grants	36,44 <mark>2</mark>	46,42
Deferred income tax liabilities	43,73 <mark>7</mark>	40,67
Current liabilities	884,317	1,012,69
Trade and other payables	411,751	456,37
Contract liabilities	226,663	245,95
Income tax liabilities	21,299	7,47
Bank borrowings	166,04 <mark>9</mark>	223,80
Lease liabilities	58,55 <mark>5</mark>	79,09
Total liabilities	1,133,078	1,177,75
Net current assets	619,628	835,25
Equity		
Share capital	83,32 <mark>6</mark>	83,32
Share premium	251,293 <mark>-</mark>	251,29
Shares held for employee share scheme	(5,517) <mark></mark>	(10,41)
Other reserves	21,188	126,02
Retained earnings	841,175	944,32
T-4-144.	4 404 405	100155
Total equity	1,191,465	1,394,55

Thank You



DISCLAIMER

This document is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person, or published, in whole or in part, for any purpose without prior written approval from TK Group (Holdings) Limited.

TK Group (Holdings) Limited and its subsidiaries ("TK Holdings" or the "Group") makes no representation or warranty (express or implied) as to the accuracy, reliability or completeness of this document. TK Group and its respective directors, employees, agents and consultants shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (expressed or implied) arising out of, or contained in or derived from, or for any omissions from this document, except liability under statute that cannot be excluded.

This presentation may contain forward looking statements concerning the Group. Forward looking statements are not statements of historical fact and actual events and results may differ materially from those described in the forward looking statements as a result of a variety of risk, uncertainties, and other factors. Forward looking statements are based on management's beliefs, opinions and estimates as of the dates the forward looking statements are made and no obligation is assumed to update forward looking statements if these beliefs, opinions and estimates should change or to reflect other future developments.

No representation or warranty (expressed or implied) is made by the Group of its respective directors, employees, advisers, agents or consultants that any forecast, projections, intentions, expectations or plans set out in this documents will be achieved, either totally or partially, or that any particular rate of return will be achieved.

This document is not:

- (i) an offer of securities for sale in Hong Kong or elsewhere; or
- (ii) an invitation to enter into an agreement to acquire, dispose of, subscribe for or underwrite securities; or related to the issue of any securities.

This document (and the information contained herein) is not for publication or distribution to any person(s) except as permitted by us.